🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Oral session Tropion Lung02 Dato-DXd + pembro ± Pt-CT, continued showing durable efficacy in a/mNSCLC, in high and low PD-L1 expression. Tolerability was as expected. TROP2 QCS-NMR showed a trend to prolonge PFS and OS in doublet and triplet cohorts. Fundación Jiménez Díaz #IIS-FJD

HERTHENA-Lung02 phase 3 study: Patritumab deruxtecan (HER3-DXd) in resistant EGFRm aNSCLC. HER3-DXd showed statistically significant improvement vs PBC in mPFS (5.8 vs 5.4m ORR 35.2% vs 25.3% . OS: NS. Manageable toxicity Very proud to participate in this trial Fundación Jiménez Díaz

AEGEAN trial outcomes in resectable NSCLC exploratory analyses based on post-Sx MRD status and genomic analysis identified a small high-risk subgroup of pts with markedly worse prognosis Very proud to participate in this trial Fundación Jiménez Díaz #IIS-FJD OncoAlert #ASCO2025 @AECAP

Fantastic activity of first in class B7H3 ADC DB1311 for patients w metastatic castration resistant #prostatecancer - we had trial open w #KevinCourtney UTSW Simmons Cancer Center & had patients benefit! ASCO #ASCO25 OncoAlert

2SMALL phase 1/2 study: Safety and efficacy of lurbinectedin + atezo in advanced SCLC: LUR + ATZ showed promising efficacy in relapsed SCLC regardless of prior exposure to IO, including those with resistance to platinum. Safety profile is manageable. #LCSM OncoAlert #SCLC

Phase 3 ADRIATIC trial: Clinical and molecular characteristics of early progressors (EPs) and long-term progression-free survivors (LTPs) in LS-SCLC. Very proud to participate in this trial Fundación Jiménez Díaz #IIS-FJD UAM Autónoma Madrid quirónsalud OncoAlert #ASCO2025 @AECAP #SCLC

CM 77T perioperative chemoimmunotherapy with Nivolumab reduces lung cancer specific mortality presented by M.Provencio at #ASCO25 OncoAlert

ALNEO phase II trial (GOIRC-01-2020-ML42316): Alectinib as neoadjuvant treatment in potentially resectable stage III ALK-positive OncoAlert #ASCO2025 @AECAP #LCSM

Lung MAP S1900E trial: relevance of co-mutations NSCLC with KRAS G12C mut+ disease #ASCO25 ⁦OncoAlert⁩

We continue to enjoy the interviews with Ana María Cuervo on the occasion of the #LVIJiménezDíazCommemorativeLecture and today it is the turn of La Razón who were able to talk to the expert the day before her master class. Thank you! larazon.es/sociedad/ana-m…

#RadOnc at #ASCO25: 📌 HA vs WBRT (brain mets) 📌 Omit RT in rectal ca post-neoadjuvant 📌 RT as non-surgical in stage III NSCLC 📌 SBRT in cervical ca 📌 RT + osimertinib (EGFR+ brain mets) 📌 Sarcoma RT biomarkers 📌 HERO trial (HER2+ breast) #OncoTwitter #ASCO2025

NeoADAURA Trial: Neoadjuvant Osi +/- CT vs CT alone in resectable EGFRm NSCLC: Osi + CT (MPR rate 26%), osi mono (25%) showed statistically significant improvement in MPR vs PBO + CT (2%). EFS data were immature Very proud to participate in this trial Fundación Jiménez Díaz #IIS-FJD

🔥🚨OncoAlert Hot Off The Press Just published Journal of Clinical Oncology in conjunction with presentation ASCO #ASCO25 ✅Results of #NeoADAURA trial of: #Neoadjuvant #Osimertinib + Chemo Vs #Osimertinib Vs #Chemo in #Resectable #EGFR+ stage II–IIIB non-small-cell #LungCancer. 👇🏻

Phase 3 IMforte: 1st Ph 3 study to show PFS and OS improvement with 1L maintenance in ES-SCLC: Lurbinectedin + atezolizumab obtained a significantly benefit in both in both IRF-PFS(HR, 0.54) and OS (HR, 0.73) vs atezo. OncoAlert #ASCO2025 @AECAP OncoAlert #ASCO2025 #LCSM

Ph3 DeLLphi-304:Tarlatamab vs CTx as 2L treatment for SCLC. Tarlatamab significantly improved mOS: 13.6 vs 8.3 m (HR 0.60) and mPFS: 4.2 vs 3.2 m (HR, 0.72) Very proud to participate in this trial Fundación Jiménez Díaz #IIS-FJD UAM Autónoma Madrid OncoAlert #ASCO2025 @AECAP OncoAlert #ASCO25

Some of the researchers who have been developing lurbinectidin PharmaMar for the treatment of SCLC for several years, following the presentation of the IMforte study at #ASCO25 Luis Paz-Ares Santi Ponce,Jon Zugazagoitia Dr. Antonio Calles 🫁🚭 Manuel Dómine, MD, PhD Instituto de Investigación Gregorio Marañón Fundación Jiménez Díaz #LCSM

Congrats to all investigators of NADIM trial. Perioperative nivolumab + chemotherapy in resectable NSCLC patients. Persistence of circulating memory B-cells during adjuvant treatment might play a crucial role in survival. Grupo Español de Cáncer de Pulmón Fundación Jiménez Díaz UAM Autónoma Madrid #IIS-FJD OncoAlert

1 semana: Jornadas de revisión del Congreso Americano de Oncología. XXV Aniversario. 25 años de experiencia con los mejores ponentes (17 Jun Madrid, 20 Jun Barcelona). Todavia estás a tiempo para inscribirte presencial o virtual. Fundación Jiménez Díaz Vall d'Hebron Doctaforum | Comunicación en salud. SEOM

Comienza PostCAO XXV aniversario (Congreso Americano Oncología. Madrid. 1º congreso que inauguró las revisiones de Congresos internacionales (post) hace 25 años y continúa haciendo una excelente formación continuada con los mejores expertos oncólogos.Fundación Jiménez Díaz Vall d’Hebron Institute of Oncology (VHIO) SEOM

PostCAO XXV en 5 horas hemos revisado los avances presntados en ASCO 25 y que han cambiado nuestra practica clínica. Mas de 200 inscritos. Muchas gracias por el apoyo estos 25 años. Próximas estaciones Barcelona 20 .6.25 y Junio 26. Este AVE no para .Fundación Jiménez Díaz Vall d’Hebron Institute of Oncology (VHIO)